CA3267295A1 - Systèmes et compositions comportant des vecteurs d'arn trans-amplifiants avec miarn - Google Patents
Systèmes et compositions comportant des vecteurs d'arn trans-amplifiants avec miarnInfo
- Publication number
- CA3267295A1 CA3267295A1 CA3267295A CA3267295A CA3267295A1 CA 3267295 A1 CA3267295 A1 CA 3267295A1 CA 3267295 A CA3267295 A CA 3267295A CA 3267295 A CA3267295 A CA 3267295A CA 3267295 A1 CA3267295 A1 CA 3267295A1
- Authority
- CA
- Canada
- Prior art keywords
- mirna
- trans
- compositions
- systems
- rna vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2022075653 | 2022-09-15 | ||
| EPPCT/EP2022/075653 | 2022-09-15 | ||
| EP2023073256 | 2023-08-24 | ||
| EPPCT/EP2023/073256 | 2023-08-24 | ||
| PCT/EP2023/075427 WO2024056856A1 (fr) | 2022-09-15 | 2023-09-15 | Systèmes et compositions comportant des vecteurs d'arn trans-amplifiants avec miarn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3267295A1 true CA3267295A1 (fr) | 2024-03-21 |
Family
ID=88092954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3267295A Pending CA3267295A1 (fr) | 2022-09-15 | 2023-09-15 | Systèmes et compositions comportant des vecteurs d'arn trans-amplifiants avec miarn |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4587579A1 (fr) |
| JP (1) | JP2025532591A (fr) |
| CN (1) | CN120239748A (fr) |
| AU (1) | AU2023342641A1 (fr) |
| CA (1) | CA3267295A1 (fr) |
| IL (1) | IL319427A (fr) |
| WO (1) | WO2024056856A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026085277A1 (fr) * | 2024-10-16 | 2026-04-23 | Amplitude Therapeutics, Inc. | Arn trans-amplifiant comportant des sites cibles de microarn |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119827A1 (fr) | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Produits de synthèse transréplicases |
| CN104072561B (zh) | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
| ES2840725T3 (es) | 2007-08-20 | 2021-07-07 | Glaxo Group Ltd | Procedimiento de producción |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2281579A1 (fr) | 2009-08-05 | 2011-02-09 | BioNTech AG | Composition de vaccin comportant un ADN modifié 5'-Cap |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| SI4043040T1 (sl) | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
| MX2013002332A (es) | 2010-08-31 | 2013-03-18 | Novartis Ag | Lipidos apropiados para suministro liposomal del arn que codifica la proteina. |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| EP4115875A1 (fr) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes ayant un rapport n:p utile pour délivrance de molécules d'arn |
| JP6059220B2 (ja) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | 核酸を含む水中油型エマルジョン |
| MX366055B (es) | 2011-08-31 | 2019-06-26 | Novartis Ag | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. |
| WO2013143555A1 (fr) | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
| WO2014071963A1 (fr) | 2012-11-09 | 2014-05-15 | Biontech Ag | Procédé pour l'expression d'arn cellulaire |
| WO2016005004A1 (fr) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilisation de séquences d'adn codant pour une séquence poly (a) |
| WO2017059902A1 (fr) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | Séquences utr 3' permettant la stabilisation d'arn |
| WO2017162266A1 (fr) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Réplicon d'arn pour une expression génique polyvalente et efficace |
| RS67724B1 (sr) | 2017-10-20 | 2026-03-31 | BioNTech SE | Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju |
| WO2020069632A1 (fr) | 2018-10-01 | 2020-04-09 | Huawei Technologies Co., Ltd. | Codeur vidéo, décodeur vidéo et procédés correspondants |
-
2023
- 2023-09-15 CA CA3267295A patent/CA3267295A1/fr active Pending
- 2023-09-15 IL IL319427A patent/IL319427A/en unknown
- 2023-09-15 WO PCT/EP2023/075427 patent/WO2024056856A1/fr not_active Ceased
- 2023-09-15 JP JP2025515766A patent/JP2025532591A/ja active Pending
- 2023-09-15 EP EP23772228.5A patent/EP4587579A1/fr active Pending
- 2023-09-15 CN CN202380078690.XA patent/CN120239748A/zh active Pending
- 2023-09-15 AU AU2023342641A patent/AU2023342641A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4587579A1 (fr) | 2025-07-23 |
| CN120239748A (zh) | 2025-07-01 |
| JP2025532591A (ja) | 2025-10-01 |
| AU2023342641A1 (en) | 2025-03-27 |
| IL319427A (en) | 2025-05-01 |
| WO2024056856A1 (fr) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4100518A4 (fr) | Vecteurs de gènes de grande taille et leur administration et leurs utilisations | |
| AU2022297443A1 (en) | Novel rna therapeutics and uses thereof | |
| AU2021380758A9 (en) | Novel rna transcript | |
| EP4317444A4 (fr) | Système d'administration d'arn plasmidique et son application | |
| CA3267295A1 (fr) | Systèmes et compositions comportant des vecteurs d'arn trans-amplifiants avec miarn | |
| HK40128346A (en) | Systems and compositions comprising trans-amplifying rna vectors with mirna | |
| EP4045654A4 (fr) | Commutateurs d'arn efficaces et systèmes d'expression associés | |
| CA3306036A1 (fr) | Vecteurs d'arn circulaires comprenant des nucléotides modifiés | |
| HK40128118A (en) | Rna constructs and uses thereof | |
| CA3269560A1 (fr) | Constructions d'arn et leurs utilisations | |
| HK40073154A (en) | Messenger rna comprising functional rna elements and uses thereof | |
| HK40073152A (en) | Endonuclease-resistant messenger rna and uses thereof | |
| HK40112935A (en) | Rna constructs and uses thereof | |
| HK40102960A (en) | Novel rna therapeutics and uses thereof | |
| HK40116956A (en) | Nucleic acid compositions and uses thereof | |
| CA3277777A1 (fr) | Nouveaux agents thérapeutiques à base d'arn et utilisations associées | |
| CA3278051A1 (fr) | Nouveaux composés thérapeutiques à arn et leurs utilisations | |
| HK40089626A (en) | Rna constructs and uses thereof | |
| AU2023901856A0 (en) | Systems and uses thereof | |
| CA3276610A1 (fr) | Agent d'arni avec nucléotides modifiés | |
| HK40081990A (en) | Ribozyme-mediated rna assembly and expression | |
| AU2022901590A0 (en) | Systems and uses thereof | |
| CA3303912A1 (fr) | Arnsi ciblant snca et ses utilisations | |
| CA3285768A1 (fr) | Assemblage et expression d'arn à médiation par ribozyme | |
| CA3262161A1 (fr) | Système de propulsion et ses applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20250310 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250609 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250609 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250609 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250610 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250610 |